Hawthorne Effect Raises $20 Million Series A to Decentralize Clinical Trials

Jodi Akin, founder and CEO of Hawthorne Effect, discusses what comes next for the clinical trials company following a Series A funding round of $20 million.
We use cookies and similar technologies on this site to collect identifiers, such as IP address, and cookie and device IDs as described in our Privacy Policy.